Rates of anxiety symptoms in patients with COPD range from 13% to 51%, which is higher than rates for patients with other chronic diseases, yet evidence underpinning the effectiveness of the various treatment options is lacking. The aim of this review was to assess the efficacy and safety of both pharmacological and psychological interventions for the management of anxiety in COPD.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a chronic lung condition characterised by the inflammation of airways and irreversible destruction of pulmonary tissue leading to progressively worsening dyspnoea and is a leading international cause of disability and death in adults [1] . Chronic Obstructive Pulmonary Disease (COPD) is a growing health problem, affecting an estimated 15 million Americans. COPD exacerbations are responsible for more than 800,000 hospital admissions in the United States each year. COPD is responsible for early mortality, high death rates and significant cost to health systems. The projection for 2020 indicates that COPD will be the third leading cause of death worldwide (from sixth in 1990) and fifth leading cause of years lost through early mortality or handicap (disability-adjusted life years) [2] .
COPD is a disease with some significant extra pulmonary effects that may contribute to the severity in individual patients (GOLD 2008 ). The two most common co morbidities of COPD are anxiety and depression. Various models could be considered to explain increased levels of anxiety and panic in patients with COPD [3, 4] . One model explains this relationship as misinterpretations of ambiguous bodily sensations (such as shortness of breath, rapid heart rate) which increase arousal, creating a positive feedback loop that results in a panic attack [5] . A crucial difference between physically healthy people and those with COPD is that in the latter, breathing, the most basic of all physical functions necessary for life, is objectively threatened (as measured by tests of lung function) and subjectively difficult. Dyspnoea can be an unpleasant and potentially frightening experience at any time, and, as the key symptom of an eventually fatal illness like COPD, it is an ambiguous sensation open to interpretation, leading to increased levels of anxiety and panic in people with COPD [6] . Also, patients with underlying stress and anxiety are more prone to smoking, which in itself is a major risk factor for development of COPD. 4 .42 to -1.26; p=0.0004, standardised mean difference -0.44; 95% CI -0.74 to -0.14; p=0.004) with the psychological studies producing greater treatment efficacy (p=0.005 for MD and p=0.02 for SMD) over pharmacological (p=0.10 for MD and p=0.20 for SMD) within sub-group analysis. Significant improvement in depression scores was noted (p=0.03), mainly driven by psychological interventions. A trend in favour of the intervention was found for the physical composite of quality of life measured by St George's Respiratory Questionnaire (standardised mean difference -0.36; 95%CI -0.74 to 0.02; p=0.06; 3 studies), but not for other measures of quality of life. No evidence of any effect was found for exercise capacity or FEV1. Psychological therapies appear to be more effective than pharmacological interventions, which have little or no effect to reduce anxiety in COPD patients. However, poor methodological quality and small sample size of studies investigating pharmacotherapy may be contributing to this discrepancy.
Anxiety can occur at any stage of COPD [7, 8] .Lifetime prevalence of Generalised Anxiety Disorder (GAD) in particular amongst patients with COPD is estimated at between 10% and 15.8% [9] .The prevalence of panic disorder in COPD population is estimated to be ten times higher than the general population [10, 11] .
Co morbid COPD and anxiety is related to poor health outcomes in terms of exercise tolerance, quality of life, COPD exacerbations [12] , inappropriate use of medications and persistence of smoking as a coping strategy for anxiety management [13] . By compromising health status, mood disorders lead to increased risk of hospitalisation and re-hospitalisation [14] and hence also increase direct and indirect costs to the health system. Psychological disorders like depression, anxiety, psychosis, alcohol abuse and drug abuse are independently associated with higher all-cause 30-day readmission rates for Medicare beneficiaries with COPD [15] .
Management strategies for the treatment of anxiety disorders in people with COPD include both pharmacological and nonpharmacological interventions. Current evidence that pharmacological therapies (antianxiety and/or antidepressant medications) provide statistically or clinically significant benefits for this group of patients is limited [16, 17] . Psychological therapies include cognitive and/or behavioural therapies, psycho-dynamic psychotherapy, inter-personal psychotherapy, non-directive therapy, support therapy and counselling [18, 19] . A recently published Cochrane review has indicated some evidence of improvement in anxiety was with psychological therapy, however, lack of statistical power limits the reliability of those findings [20] .
Despite of anxiety in COPD being such an important issue, there is an apparent lack of good quality and well powered RCTs addressing the treatment for patients with anxiety and COPD, hence we have conducted a systematic meta analysis including the RCTs of pharmacological and psychological interventions for patients with clinical anxiety and diagnosed COPD.
METHODS
A pre-specified protocol was established prior to commencement of the review (published on PROSPERO ID: 2017:CRD42017056172).
Search strategy
Two Cochrane Specialised Registers were searched with complementary screening of Medline, PsycINFO and CENTRAL (see search strategy in Appendix). Reference lists of included studies and online clinical trial registries (http://apps.who.int/trialsearch/) were also screened using key words of anxiety AND COPD.
Study selection
Randomised controlled trials (RCTs) and cross-over studies of pharmacological or psychological interventions for patients (age >40 years) with diagnosed COPD and co-existing anxiety (confirmed by recognised diagnostic criteria or validated measurement scale) were identified for inclusion. Studies where patients did not have confirmed COPD diagnosis or confirmed anxiety levels (using a formal questionnaire/test) were excluded.
Data extraction
Data was screened and extracted by two independent review authors (ZU and KC) with meta-analyses of outcomes performed using Review Manager Software Version 5.3. Pilot tested standardised data extraction templates were used with double data entry for characteristics of studies, results and risk of bias assessments. Any discrepancies were resolved through consensus.
Intervention and comparator description:
Pharmacological and psychological interventions for the treatment of anxiety in COPD were included. Pharmacological interventions considered for inclusion were antidepressants or anxiolytics that are compared to placebo, usual care or no treatment. Psychological interventions that were considered included all types of formal psychotherapy as mentioned above. Comparisons included usual care, education only (e.g., written or oral education including provision of information about physical or mental health issues during a consultation or during a visit with another health professional where no formal counselling or psychological therapy was provided) or cointervention (only if the co-intervention was also used in the control arm of the study).
Outcomes:
The primary outcome was change in anxiety from baseline to follow-up between groups.
Secondary outcomes were change in depression, quality of life, hospital utilisation (readmission rates and length of stay), exercise capacity (e.g., six minute walking distance) and adverse events.
Quality assessment and risk of bias
A quality assessment was conducted using standard Cochrane methodology via the risk of bias tool. This data was assessed and entered into Review Manager Software version 5.3, by two independent review authors (ZU and KC). Outcomes of interest include: Random sequence generation, allocation concealment, blinding of participants and outcome assessors, incomplete outcome data, selective reporting and other forms of bias.
Data analysis
Final follow-up outcomes were used as the primary end-point for all studies. Available data for meta-analysis was summarised using random effect model and reported as standardised mean difference (SMD) or/ and mean difference (MD). Meta-analysis was conducted comparing intervention and control arms of each study identified for inclusion. In the presence of considerable heterogeneity (visual inspection of the data combined with I-squared statistic of >75% to 100%) narrative synthesis was used in place of meta-analysis.
Sub-group analysis, heterogeneity and sensitivity analysis
Subgroup analyses occurred for pharmacological versus psychological interventions for the primary outcome of anxiety.
RESULTS
A total of 1,790 citations resulted in nine included studies (five pharmacological and four psychological) as presented in Figure  1 .
The primary reasons for study exclusion were: minimum anxiety score not met or unable to get the baseline anxiety scores despite attempts to contact the authors, no appropriate comparator arm and anxiety outcomes not reported. Seven of the nine studies were RCT's, four psychological and three pharmacological, with the two remaining pharmacological studies being cross-over trials using a two-week washout period (see Table 1 ). Sample size ranged from 4 to 238 participants. Psychological interventions included: Psychoeducation therapy, CBT or a combination of these combined with co-interventions such as exercise and physiotherapy. Pharmacologi-cal investigations included: paroxetine (two studies), citalopram hydrobromide, buspirone and doxepin hydrochloride. 
Quality assessment and risk of bias
Random sequence generation and allocation concealment (selection bias) were assessed as unclear risk of bias for most studies due to inadequate reporting of methodology (see Table 2 ). Three studies reported blinding of participants (performance bias) whilst three studies also reported blinding of outcome assessors (detection bias). Of note, it is diffi-cult to blind psychological interventions as participants are aware of which treatment type they are receiving due to ethical considerations and full disclosure requirements. Attrition bias (reporting of incomplete outcome data) and reporting bias (selective reporting of outcome variables) were adequately addressed in six and five the nine studies respectively, whilst being unclear or inadequate in the remaining trials. Other types of bias were identified in three other trials One study (Eiser 2005) reported significant side effects from paroxetine in four of the 14 intervention subjects, resulting in a change to lofepramine 140mg, which subsequently may have affected the integrity of results. Another study (Singh 1993 ) including only n=10 subjects in each arm, included a population of only male subjects with authors reporting that dose and duration of treatment were a concern for lack of effect reported. Moreover, there was a population concern as baseline anxiety levels differed from initial screening levels. As such, patients had at most, mild anxiety. For the final study (Subbe 2004) raw data was obtained from study authors for COPD patients with baseline anxiety, resulted in inclusion of only n=4 participants in total.
Two males were in the intervention arm and two females in the control arm, adding to the imbalance in participant data.
Effects of interventions
Anxiety: Meta-analysis of all nine completed trials revealed significant reductions to anxiety in the treatment arm (MD -2.67; 95%CI -3.88 to -1.47; p< 0.0001) with psychological studies producing greater treatment efficacy (p< 0.0001; 376 subjects) over pharmacological (p= 0.10; 81 subjects) within sub-group analysis. As significant heterogeneity was observed among the psychological sub-group (I 2 = 53%) the data was re-analysed using the random effect model. Statistical significance was maintained (MD -2.84; 95%CI -4.42 to -1.26; p= 0.0004) with psychological studies still (MD -3.50; 95% CI -5.93 to -1.06; p= 0.005) outperforming pharmacological (MD -2.30; 95% CI -4.48 to 0.41; p= 0.10; Figure 2) . Minimal Important Difference (MID) for HADS-A in COPD patients has been reported as 1.5. We were unable to find a reference range for MID for BAI and STAI in COPD patients.
Figure 2.
Meta-analysis of pharmacological and psychological interventions compared to usual care/control population for the outcome of anxiety using the random effect model Studies included in the review, used different scales to assess levels of anxiety. One pharmacological and three psychological studies used BAI, whereas two pharmacological and one psychological studies reported anxiety as HADS-A and remaining two pharmacological studies used STAI to report anxiety scores/symptom. Hence, we also conducted a meta-analysis using standardised mean difference to account for different tools to be pooled together. The effect of intervention was still significant (SMD -0.44; 95% CI -0.74 to -0.14; p=0.004, Figure 3 ) with psychological interventions producing more significant effect (p= 0.02 for SMD) as compared to the pharmacotherapy (p= 0.20 for SMD). However it is important to note that Kunik et al compared education vs. CBT and significant reduction was noted post intervention for both the arms though not between the two groups likely as both were a type of intervention Exercise Capacity: No significant difference in exercise capacity was noted in any of the pharmacological or psychological trials assessing exercise capacity as an outcome ( Figure 5 ).
Hospital Admissions. Only one of the nine trials formally assessed and reported the hospital readmission rate (Usmani 2018 ). There were fewer COPD-related hospital admissions in the intervention group compared to the placebo group during the fourmonth treatment phase (1/10 and 6/12 respectively; p=0.050).
Side effects: Medication related side effects were reported in pharmacological studies more in the treatment arm however no adverse event was reported related to the medication No significant side effects were reported in any of the psychological studies. 
DISCUSSION AND SUMMARY
Anxiety associated with COPD increases the burden of overall morbidity not only on the psychological parameters but also on the physical symptoms and overall quality of life. This meta analyses is the first in our knowledge to have systematically analysed the effects of various treatment modalities and the quality of evidence which exists for management of anxiety in COPD.
There are some limitations of the review. It should be acknowledged that pharmacological and psychological studies are heterogeneous in terms of measures of outcomes and treatment types and though we have analysed them together in our main analysis, each type of intervention may be more beneficial for a particular subset of patients. Overall, there was a lack of randomised controlled trails and only nine studies were eligible to be included according to our predefined inclusion criteria. Majority of the studies particularly, the pharmacological studies had small sample sizes. The majority of the studies did not report sequence generation and allocation concealment. Psychological studies had the limitation of lack of blinding at participant level. However most of the studies were relatively free of reporting bias. For most of the psychological interventions adverse events, length of stay, readmission rates and objective markers of lung disease such as FEV₁ were not included as an outcome in any of the three included studies. Psychological studies included participants with both anxiety and depression, which may limit generalisability of results.
Overall, significant improvement in anxiety symptoms was noted with treatment, with psychological interventions having most of the effect. In other words, psychological interventions appear to have the greatest efficacy for anxiety management over pharmacological treatments; however, the strength of the evidence is limited by the paucity of data due to the small number of included studies. Associated reduction was also noted in co-existing depression symptoms in most of the studies. Quality of life and exercise capacity were either not reported or if reported no significant change was noted. One study reported reduction in hospital readmission rate but this was based on small sample size and should be interpreted with caution. Overall more side effects were noted with pharmacological interventions as expected.
CONCLUSIONS
Based upon the available evidence, psychological therapies appear to be more effective than pharmacological interventions to reduce anxiety in COPD patients. However, poor methodological quality and/or small sample size of studies investigating pharmacotherapy may be contributing to this discrepancy. Except for depression, significant change was not noted in other parameters of quality of life. However, because of the short follow up period of the studies it is possible that the benefit might be seen in the longer term. Methodologically rigorous trials with much longer follow up period and inclusion of health economics outcomes are required for patients suffering from co existing anxiety and COPD. 
